QuidelOrtho Corporation (QDEL) fair value analysis

Nasdaq · Updated 2026-09-07

QuidelOrtho Corporation is a healthcare company that develops, manufactures, and distributes diagnostic testing solutions, including products for infectious disease, cardiology, and women's health applications. The company operates globally with a presence across multiple continents to serve healthcare providers, laboratories, and patients worldwide.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, QDEL is trading at a 10–25% discount to estimated fair value.

QDEL currently ranks #51 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $17.71
Sector: Healthcare
12-month range: $12.64–$31.25

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Declining
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range

What our data shows for QDEL

Our model validated 15 trailing price-to-earnings windows for QDEL, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $12.64–$31.25.
The 14-day relative strength index sits at a neutral 38.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for QDEL
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent QDEL news

TickrTrends' derived news-sentiment signal for QDEL is currently mixed, computed from recent coverage.

Quidel Q1 2026 Earnings Preview (NASDAQ:QDEL) (seekingalpha.com, 2026-05-04)
TickrTrends take: Quidel operates in the Healthcare sector, where diagnostic and testing companies face cyclical demand patterns that can significantly impact earnings predictability and valuation multiples. TickrTrends currently derives an undervalued verdict for QDEL, suggesting the market may not be fully pricing in the company's earnings potential or competitive positioning within diagnostics. Investors focused on valuation should monitor whether Q1 2026 results demonstrate the revenue stability and margin performance necessary to justify a higher valuation multiple than the stock currently commands.
Quidel Q3 2025 Earnings Preview (NASDAQ:QDEL) (seekingalpha.com, 2025-11-04)
TickrTrends take: Quidel's upcoming third quarter 2025 earnings report presents an opportunity for investors tracking the Healthcare sector to assess whether the company's operational performance justifies TickrTrends' current undervalued designation. Earnings results will provide concrete data on revenue trends, margin performance, and cash generation that either support or challenge the current valuation assessment. Given the market's evaluation of QDEL as undervalued, particular attention should be paid to whether management commentary and forward guidance suggest the company can narrow any gap between its current trading price and intrinsic value.

What people are saying

Follow the QDEL conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # QDEL Weekly Indicator Summary TickrTrends' derived indicators for QDEL in the Healthcare sector show a shift this week as the momentum indicator, which had been rated B, is no longer present in the current assessment. The stock maintains an Undervalued valuation verdict. This change in momentum status represents the only tracked alteration to the indicator set from the previous week.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is QDEL stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), QDEL is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is QDEL's TickrTrends verdict?

QDEL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does QDEL compare to other Healthcare stocks?

QDEL ranks #51 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is QDEL overbought or oversold?

QDEL's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

QDEL vs BDX · QDEL vs EW · QDEL vs EXEL · QDEL vs GMAB · QDEL vs HCA